Pb2278 pretreatment Serum 25(oh) Vitamin D as Predictor of Event‐ Free Survival in Lymphoid Malignancies

Abstract

Background:Vitamin D was investigated as a prective factor in lymphoid malignancies recently.Aims:Assessment of 25(OH) vitamin D status in lymphoid malignacies before active treatment and its influence on event‐free survival (EFS).Methods:Study included 153 patients, median age 58(18‐84) years with diagnose: diffuse large B cell lymphoma‐70, Hodgkin lymphoma‐22, chronic lymphocitic leukemia‐21, follicular lymphoma‐20 and multiple myeloma‐20, who had pretreatment 25(OH) vitamin D level. Comorbidities were assessed by Cumulative comorbidity index (CIRS). Patients were treated with immunochemotherapy and followed for event‐free survival for median 38(2‐53) months.Event was defined as progression or death.Results:Pretreatment serum 25(OH) vitamin D was 34,4 ± 13,6 nmol/l, without significant difference between lymphoma subgroups (ANOVA p = 0,069). Multivariate Cox regression for EFS showed 25(OH)D<25nmol/l (HR 2,732, 95%CI 1,37‐5,44), elevated LDH (HR 3,79, 95%CI 1,87‐7,66) and CIRS > 3 (HR 2,88, 95%CI 1,43‐5,78) as significant parameters for EFS.Summary/Conclusion:Average pretreatment 25(OH)D level in lymphoid malignancies is low. Severe deficiency, 25(OH)D <25nmol/l, is strong predictor of EFS in analysed group of patients.

Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: a meta-analysis

“… 44-46 A flow diagram of the article selection process is shown in Figure 1 . Twenty-two articles were excluded for the following reasons: duplicate publications from overlapping cohorts, 47,48 insufficient data about primary end points, 49-60 and transplantations including many nonmalignancies or unidentified diseases. 61-68 The characteristics of each study are summarized in Table 1 .…”